MA50034B1 - Composition de stimulation ovarienne contrôlée - Google Patents

Composition de stimulation ovarienne contrôlée

Info

Publication number
MA50034B1
MA50034B1 MA50034A MA50034A MA50034B1 MA 50034 B1 MA50034 B1 MA 50034B1 MA 50034 A MA50034 A MA 50034A MA 50034 A MA50034 A MA 50034A MA 50034 B1 MA50034 B1 MA 50034B1
Authority
MA
Morocco
Prior art keywords
ovarian stimulation
controlled ovarian
stimulation composition
composition
fsh
Prior art date
Application number
MA50034A
Other languages
English (en)
Other versions
MA50034A (fr
Inventor
Lisbeth Helmgaard
Bjarke Mirner Klein
Saez Joan-Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA50034A publication Critical patent/MA50034A/fr
Publication of MA50034B1 publication Critical patent/MA50034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des préparations contenant de la fsh, par exemple de la fsh recombinante, destinées à être utilisées dans le traitement de l'infertilité chez des patients ayant un taux élevé d'amh et un faible poids corporel.
MA50034A 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée MA50034B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (fr) 2017-09-01 2018-08-31 Composition destinée à la stimulation ovarienne contrôlée

Publications (2)

Publication Number Publication Date
MA50034A MA50034A (fr) 2021-05-12
MA50034B1 true MA50034B1 (fr) 2022-02-28

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée
MA056224A MA56224A (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA056224A MA56224A (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Country Status (30)

Country Link
US (2) US11744879B2 (fr)
EP (2) EP3675894B1 (fr)
JP (2) JP6856819B2 (fr)
KR (1) KR20200045543A (fr)
CN (1) CN111050787A (fr)
AR (1) AR112541A1 (fr)
AU (1) AU2018326556A1 (fr)
BR (1) BR112020003379A2 (fr)
CA (1) CA3073624A1 (fr)
CL (1) CL2020000482A1 (fr)
DK (1) DK3675894T3 (fr)
EA (1) EA202090480A1 (fr)
ES (1) ES2904787T3 (fr)
HR (1) HRP20211802T1 (fr)
HU (1) HUE056726T2 (fr)
IL (1) IL272763B2 (fr)
JO (1) JOP20200034A1 (fr)
LT (1) LT3675894T (fr)
MA (2) MA50034B1 (fr)
MD (1) MD3675894T2 (fr)
MX (1) MX2020002235A (fr)
PH (1) PH12020500404A1 (fr)
PL (1) PL3675894T3 (fr)
PT (1) PT3675894T (fr)
RS (1) RS62810B1 (fr)
SG (1) SG11202003840QA (fr)
SI (1) SI3675894T1 (fr)
TW (1) TWI749255B (fr)
UA (1) UA126869C2 (fr)
WO (1) WO2019043143A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217113T5 (es) * 2000-01-27 2008-11-01 Laboratoires Serono Sa Uso de fsh para tratar infertilidad.
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (fr) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Dérivés d'aloé-émodine et leur utilisation pour le traitement du cancer
WO2012042381A1 (fr) 2010-09-29 2012-04-05 Ferring B.V. Composition destinée à une stimulation ovarienne contrôlée
EP2717904A1 (fr) 2011-06-06 2014-04-16 Ferring BV Préparation pharmaceutique
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
BR112016023668A2 (pt) * 2014-04-18 2017-10-17 Glycotope Gmbh hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado
EP4289477A3 (fr) 2015-02-26 2024-02-21 Ferring B.V. Menotropin pour le traitement de l'infertilité
JP7079094B2 (ja) * 2015-04-17 2022-06-01 フェリング ベスローテン フェンノートシャップ 不妊症の処置のための組成物
CN107532172A (zh) 2015-04-24 2018-01-02 辉凌公司 产生***的方法
WO2016207353A1 (fr) 2015-06-26 2016-12-29 Ferring B.V. Procédés de purification et/ou d'inactivation virale
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
KR20210079276A (ko) 2018-10-17 2021-06-29 훼링 비.브이. 제어된 난소 자극을 위한 조성물 및 방법

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
SG11202003840QA (en) 2020-05-28
US20200197493A1 (en) 2020-06-25
PT3675894T (pt) 2022-01-25
ES2904787T3 (es) 2022-04-06
RS62810B1 (sr) 2022-02-28
JOP20200034A1 (ar) 2020-02-13
IL272763B2 (en) 2024-02-01
PH12020500404A1 (en) 2021-03-01
JP7373479B2 (ja) 2023-11-02
CA3073624A1 (fr) 2019-03-07
WO2019043143A1 (fr) 2019-03-07
EA202090480A1 (ru) 2020-07-20
MX2020002235A (es) 2020-07-20
CL2020000482A1 (es) 2020-06-26
MA56224A (fr) 2022-04-20
HRP20211802T1 (hr) 2022-03-04
UA126869C2 (uk) 2023-02-15
JP2020528071A (ja) 2020-09-17
IL272763A (en) 2020-04-30
AU2018326556A1 (en) 2020-03-05
JP2021046398A (ja) 2021-03-25
EP3675894B1 (fr) 2021-11-03
AR112541A1 (es) 2019-11-06
BR112020003379A2 (pt) 2020-08-25
TWI749255B (zh) 2021-12-11
JP6856819B2 (ja) 2021-04-14
MA50034A (fr) 2021-05-12
IL272763B1 (en) 2023-10-01
DK3675894T3 (da) 2022-01-24
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
US11744879B2 (en) 2023-09-05
EP3973982A1 (fr) 2022-03-30
HUE056726T2 (hu) 2022-03-28
TW201919687A (zh) 2019-06-01
MD3675894T2 (ro) 2022-03-31
SI3675894T1 (sl) 2022-01-31
CN111050787A (zh) 2020-04-21
KR20200045543A (ko) 2020-05-04
EP3675894A1 (fr) 2020-07-08

Similar Documents

Publication Publication Date Title
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2020002869A (es) Compuestos de pirazolopirimidinona y usos de los mismos.
MX2019012233A (es) Anticuerpos anti-sirpa.
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
EP4338804A3 (fr) Formulations pour la pulvérisation d'épinéphrine
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2019015071A (es) Composiciones y metodos para tratar tauopatias.
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MA46548A (fr) Fsh pour le traitement de l'infertilité
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
EA201991147A1 (ru) ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2021013356A (es) Tratamiento y prevencion de enfermedades metabolicas.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
CR20200127A (es) Anticuerpo anti-pacap
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
BR112022010905A2 (pt) Formulações de anticorpos anti-cd38 para administração subcutânea
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
MA50034B1 (fr) Composition de stimulation ovarienne contrôlée
MX2021002936A (es) Uso de recambio plasmatico de bajo volumen para el tratamiento de la enfermedad de alzheimer en etapas temprana y moderada.
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.